Form 4: Cumberland Pharmaceuticals Director Caroline Young Acquires Additional Shares Through 10b5-1 Trading Plan

Director Caroline Young of Cumberland Pharmaceuticals increased her holdings through a pre-arranged 10b5-1 trading plan, acquiring shares in multiple transactions between March 3, 2025, and March 31, 2025.

Summary

• Caroline Young, a director at Cumberland Pharmaceuticals, acquired additional shares of the company's common stock.
• The purchases were made between March 3, 2025, and March 31, 2025.
• All transactions were executed automatically under a pre-existing Rule 10b5-1 trading plan adopted on November 14, 2024.
• The number of shares acquired in each transaction ranged from 3 to 4.
• The prices paid per share varied from $4.20 to $6.75.
• Following these transactions, Ms. Young directly owns 32,392 shares of Cumberland Pharmaceuticals.
• The filing was signed by John Hamm as attorney-in-fact for Caroline Young on April 4, 2025.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing detailing stock purchases by a director, indicating a neutral sentiment.

Positives

• The director's continued investment in the company may signal confidence in its future prospects.
• The use of a 10b5-1 trading plan ensures that the transactions are pre-planned and not based on insider information.

Industry Context

Form 4 filings are standard practice and provide transparency into the trading activities of company insiders, allowing investors to track ownership changes and potential alignment of interests.

Stakeholder Impact

• Shareholders may view the director's stock purchases as a positive sign, reflecting confidence in the company's prospects.

Key Dates

Keywords

Cumberland Pharmaceuticals, CPIX, Caroline Young, Director, Share Acquisition, Form 4, 10b5-1 Trading Plan, Beneficial Ownership